[Chromogenic substrate as antidote against the thrombin inhibitor Melagatran?].
It could be shown in vitro that a chromogenic substrate (Chromozym TH, Roche Mannheim) acts at least partially as antidote against the new thrombin inhibitor Melagatran (AstraZeneca, Mölndal, Sweden). It is discussed that this antidote effect of a chromogenic substrate might be due to a substrate competition of fibrinogen, thrombin inhibitor, and chromogenic substrate for thrombin. Further animal experiments will clarify whether this in vitro observation is of practical relevance in vivo, too.
Bodendiek
I
I
I. Medizinische Universitätsklinik Kiel, Schittenhelmstrasse 12, 24105 Kiel.
Lentz
S
S
Seeger
M
M
Bruhn
H D
HD
D000931:Antidotes; D000991:Antithrombins / Q000633:toxicity*; D001384:Azetidines; D001596:Benzylamines; D002863:Chromogenic Compounds / Q000627:therapeutic use*; D005998:Glycine / Q000031:analogs & derivatives* / Q000633:toxicity*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use*
D000931:Antidotes; D000991:Antithrombins; D001384:Azetidines; D001596:Benzylamines; D002863:Chromogenic Compounds; D009842:Oligopeptides; C109573:melagatran; C014413:chromozym TH; D005998:Glycine